Webinar Invitation: Use of ASA for Prevention of vascular events: What do we tell people to do now?
Heart & Stroke knowledge translation for health professionals webinar
Use of Acetylsalicylic Acid (ASA) for Prevention of vascular events: What do we tell people to do now?
Date and Time: Tuesday March 24, 2020 from 12:00 to 13:00 EST
- Theodore Wein, MD, FRCPC, FAHA, Assistant Professor of Neurology and Neurosurgery, McGill University, Stroke Prevention Clinic, Montreal General Hospital
- Jeff Habert, MD, CCFP, FCFP, Assistant Professor, Department of Family and Community Medicine, University of Toronto
- Christine Papoushek, PharmD, Department of Pharmacy, University Health Network
Moderator: Patrice Lindsay, RN, PhD
Intended Audience: This webinar is intended for all healthcare professionals caring for people with heart conditions, stroke or vascular cognitive impairment across all settings and stages of care; system leaders and funders involved in planning and service delivery; researchers; Heart & Stroke employees; and students from across health-related disciplines. Members of the public, particularly those living or caring for someone with related health conditions, may also find this information helpful.
Language: This webinar is scheduled in English and will also be offered in French (date TBD).
About this presentation: Emerging evidence has changed the way we think about the role of ASA in the prevention of stroke, heart conditions, vascular cognitive impairment and peripheral artery disease. During this webinar, experts will review the recent evidence, present the new Canadian Best Practice Guidelines on this topic, and provide practical examples of who these apply to, roles and responsibilities of all health professionals in educating patients and the public, and identifying the areas where research gaps still exist. The audience will be able to post questions that will be addressed by a panel of experts at the end of the webinar.
The webinar will be archived and available for viewing on the CSBPR website .
Participants of this program will be able to:
- Appraise the current evidence for the use of ASA in primary and secondary prevention of vascular disease.
- Interpret and apply guidelines for the use of ASA for primary prevention.
- Identify appropriate patients start, stop or continue ASA.
- Discuss the gaps in research evidence to guide practice for some populations.
For any questions please e-mail: KTHP@heartandstroke.ca